medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2022-16-23-199-204medsovet-7327Research ArticleЭНДОКРИНОЛОГИЯENDOCRINOLOGYФиксированные комбинации сахароснижающих препаратов в лечении пациентов с сахарным диабетом 2-го типаFixed combinations of hypoglycemic drugs in the treatment of patients with type 2 diabeteshttps://orcid.org/0000-0001-6123-5610ВербовойА. Ф.VerbovoyA. F.

Вербовой Андрей Феликсович – доктор медицинских наук, профессор, заведующий кафедрой эндокринологии.

443099, Самара, ул. Чапаевская, д. 89

Andrey F. Verbovoy - Dr. Sci. (Med.), Professor, Head of the Department of Endocrinology, Samara State Medical University.

89, Chapaevskaya St., Samara, 443099

diabet@samtel.ruВербоваяН. И.VerbovayaN. I.

Вербовая Нэлли Ильинична - доктор медицинских наук, профессор.

443099, Самара, ул. Чапаевская, д. 89

Nelly I. Verbovaya - Dr. Sci. (Med.), Professor, Samara State Medical University.

89, Chapaevskaya St., Samara, 443099

diabet@samtel.ruhttps://orcid.org/0000-0001-6678-6411ДолгихЮ. А.DolgikhYu. A.

Долгих Юлия Александровна - кандидат медицинских наук, ассистент кафедры эндокринологии.

443099, Самара, ул. Чапаевская, д. 89

Yulia A. Dolgikh - Cand. Sci. (Med.), Assistant at the Department of Endocrinology, Samara State Medical University.

89, Chapaevskaya St., Samara, 443099

yulyadoll@mail.ruСамарский государственный медицинский университетРоссияSamara State Medical UniversityRussian Federation202220012023023199204Copyright © Вербовой А.Ф., Вербовая Н.И., Долгих Ю.А., 20232023Вербовой А.Ф., Вербовая Н.И., Долгих Ю.А.Verbovoy A.F., Verbovaya N.I., Dolgikh Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/7327

Распространенность сахарного диабета (СД) в нашей стране достаточно велика. При этом большая часть приходится на СД2. Данная патология характеризуется достаточно высокой инвалидизацией и смертностью. Основной причиной летальных исходов при СД2 являются сердечно-сосудистые заболевания – около 52,0%. Важной причиной развития и прогрессирования этих осложнений является отсутствие компенсации диабета, что является в настоящее время серьезной проблемой. Так, по статистике, в России доля компенсированных пациентов с СД2 с уровнем гликированного гемоглобина менее 7,0% составляет лишь чуть больше половины всех больных. Причинами недостаточной компенсации заболевания могут быть такие факторы, как отсутствие обучения пациентов и самоконтроля, а также низкая приверженность пациента к соблюдению правил приема сахароснижающих препаратов. Использование пролонгированных форм препаратов, а также комбинированных лекарственных средств повышает приверженность пациентов к терапии. Среди таблетированных лекарственных средств для лечения СД2 наиболее часто назначаемыми препаратами являются метформин и производные сульфонил-мочевины (СМ). Совместное назначение этих групп препаратов улучшает гликемический контроль пациентов. Существуют лекарственные средства, содержащие фиксированные комбинации метформина и производных СМ. Например, препарат, содержащий 2,5 мг глибенкламида и 400 мг метформина, а также препарат с более высокой дозой метформина в двух комбинациях: 2,5 мг глибенкламида и 500 мг метформина и 5 мг глибенкламида и 500 мг метформина, а также препарат в качестве производного СМ, содержащий 2 мг глимепирида и 500 мг метформина. Такие дозировки являются удобными для приема пациентов и дальнейшего титрования, а также имеют низкий риск гипогликемии.

The prevalence of diabetes mellitus (DM) in our country is quite high. Most of them are type 2 diabetes. This pathology is characterized by a rather high disability and mortality. The main cause of deaths in type 2 diabetes are cardiovascular diseases – about 52.0%. An important reason for the development and progression of these complications is the lack of compensation for diabetes, which is currently a serious problem. Thus, according to statistics in Russia, the proportion of compensated patients with type 2 diabetes with a glycated hemoglobin level of less than 7.0% is only slightly more than half of all patients. The reasons for insufficient compensation of the disease may be such factors as the lack of patient education and self-control, as well as the patient’s low adherence to compliance with the rules for taking hypoglycemic drugs. The use of prolonged forms of drugs, as well as combined drugs, increases the adherence of patients to therapy. Among oral medications for the treatment of type 2 diabetes, the most commonly prescribed drugs are metformin and sulfonylurea (SM) derivatives. The joint appointment of these groups of drugs improves glycemic control of patients. There are drugs containing fixed combinations of metformin and SM derivatives. For example, containing 2.5 mg/tab of glibenclamide and 400 mg/tab of metformin, and 2.5 mg/tab of glib-enclamide and 500 mg/tab of metformin and 5 mg/tab of glibenclamide and 500 mg/tab of metformin, as well, containing 2 mg/tab of glimepiride and 500 mg/tab metformin. Such dosages are convenient for patient intake and further titration, also have a low risk of hypoglycemia.

сахарный диабет 2-го типасахароснижающая терапияметформинглибенкламидглимепиридtype 2 diabetes mellitushypoglycemic therapymetforminglibenclamideglimepirideReferencesДедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021;24(3):204–221. https://doi.org/10.14341/DM12759.Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.А. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes Mellitus. 2021;24(3):204–221. (In Russ.) https://doi.org/10.14341/DM12759.Дедов И.И., Шестакова М.В., Майоров А.Ю. (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 9-й выпуск. Сахарный диабет. 2019;22(Suppl. 1):1–144. https://doi.org/10.14341/DM221S1.Dedov I.I., Shestakova M.V., Mayorov A.Yu. (eds.). Standards of specialized diabetes care. 9th ed. Diabetes Mellitus. 2019;22(Suppl. 1):1–144. (In Russ.) https://doi.org/10.14341/DM221S1.Викулова О.К., Железнякова А.В., Исаков М.А., Серков А.А., Шестакова М.В., Дедов И.И. Динамический анализ состояния углеводного обмена в субъектах Российской Федерации по данным мобильного медицинского центра (Диамодуль) и регистра сахарного диабета Российской Федерации. Сахарный диабет. 2020;23(2):104–112. https://doi.org/10.14341/DM12327.Vikulova O.K., Zheleznyakova A.V., Isakov M.A., Serkov A.A., Shestakova M.V., Dedov I.I. et al. Dynamic analysis of glycaemic control parameters in the regions of Russia according to the data of the mobile medical centre (Diamodul) and Federal Diabetes Register. Diabetes Mellitus. 2020;23(2):104–112. (In Russ.) https://doi.org/10.14341/DM12327.Дедов И.И., Шестакова М.В., Майоров А.Ю., Шамхалова М.Ш., Сухарева О.Ю., Галстян Г.Р. и др. Сахарный диабет 2 типа у взрослых. Клинические рекомендации. Сахарный диабет. 2020;23(2 Suppl.):4–102. https://doi.org/10.14341/DM12507.Dedov I.I., Shestakova M.V., Mayorov A.Y., Shamkhalova M.S., Sukhareva O.Yu., Galstyan G.R. et al. Diabetes mellitus type 2 in adults. Diabetes Mellitus. 2020;23(2 Suppl.):4–102. (In Russ.) https://doi.org/10.14341/DM12507.Shu A.D. Adherence to osteoporosis medication after patient and physician brief education: post hoc analysis of a randomized controller trial. Am J Manag Care. 2009;15(7):417–424. Available at: https://pubmed.ncbi.nlm.nih.gov/19589009.Shu A.D. Adherence to osteoporosis medication after patient and physician brief education: post hoc analysis of a randomized controller trial. Am J Manag Care. 2009;15(7):417–424. Available at: https://pubmed.ncbi.nlm.nih.gov/19589009.Morris A.D. Considerations in assessing effectiveness and costs of diabetes care: lessons from DARTS. Diabetes Metab Res Rev. 2002;8(3):32–35. https://doi.org/10.1002/dmrr.295.Morris A.D. Considerations in assessing effectiveness and costs of diabetes care: lessons from DARTS. Diabetes Metab Res Rev. 2002;8(3):32–35. https://doi.org/10.1002/dmrr.295.Rojas L.B., Gomes M.B. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5(1):6. https://doi.org/10.1186/1758-5996-5-6.Rojas L.B., Gomes M.B. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5(1):6. https://doi.org/10.1186/1758-5996-5-6.Markowicz-Piasecka M., Huttunen K.M., Mateusiak L., Mikiciuk-Olasik E., Sikora J. Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics. Curr Pharm Des. 2017;23(17):2532–2550. https://doi.org/10.2174/1381612822666161201152941.Markowicz-Piasecka M., Huttunen K.M., Mateusiak L., Mikiciuk-Olasik E., Sikora J. Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics. Curr Pharm Des. 2017;23(17):2532–2550. https://doi.org/10.2174/1381612822666161201152941.Rena G., Hardie G.G., Pearson E.A. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585. https://doi.org/10.1007/s00125-017-4342-z.Rena G., Hardie G.G., Pearson E.A. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585. https://doi.org/10.1007/s00125-017-4342-z.Вербовой А.Ф., Вербовая Н.И., Ломонова Т.В., Долгих Ю.А. Метформин – время расширять показания? РМЖ. 2021;(2):37–41. Режим доступа: https://www.rmj.ru/articles/endokrinologiya/Metformin_vremya_rasshiryaty_pokazaniya/#ixzz7HyWgr6AV.Verbovoy A.F., Verbovaya N.I., Lomonova T.V., Dolgikh Yu.A. Metformin: is it time to expand the indications? RMJ. 2021;(2):37–41. (In Russ.) Available at: https://www.rmj.ru/articles/endokrinologiya/Metformin_vremya_rasshiryaty_pokazaniya/#ixzz7HyWgr6AV.Древаль А.В., Мисникова И.В., Триголосова И.В., Тишенина Р.С. Влияние метформина на углеводный и липидный обмен у лиц с ранними нарушениями углеводного обмена. Сахарный диабет. 2010;13(2):63–67. https://doi.org/10.14341/2072-0351-5676.Dreval’ A.V., Misnikova I.V., Trigolosova I.V., Tishenina R.S. Metformin effects to carbohydrate and lipids metabolism in impaired glucose tolerance patients. Diabetes Mellitus. 2010;13(2):63–67. (In Russ.) https://doi.org/10.14341/2072-0351-5676.Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865. Available at: https://pubmed.ncbi.nlm.nih.gov/9742977.Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865. Available at: https://pubmed.ncbi.nlm.nih.gov/9742977.Scarpello J.H. Improving survival with metformin: the evidence base today. Diabetes Metab. 2003;29(4):636–643. https://doi.org/10.1016/s1262-3636(03)72786-4.Scarpello J.H. Improving survival with metformin: the evidence base today. Diabetes Metab. 2003;29(4):636–643. https://doi.org/10.1016/s1262-3636(03)72786-4.McFarlane S.I., Banerij M., Sowers J.R. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001;86:713–718. https://doi.org/10.1210/jcem.86.2.7202.McFarlane S.I., Banerij M., Sowers J.R. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001;86:713–718. https://doi.org/10.1210/jcem.86.2.7202.Davidson M.B., Peters A.L. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997;102(1):99–110. https://doi.org/10.1016/s0002-9343(96)00353-1.Davidson M.B., Peters A.L. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997;102(1):99–110. https://doi.org/10.1016/s0002-9343(96)00353-1.Phung O.J., Sobieraj D.M., Engel S.S., Rajpathak S.N. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and metaanalysis. Diabetes Obes Metab. 2014;16(5):410–417. https://doi.org/10.1111/dom.12233.Phung O.J., Sobieraj D.M., Engel S.S., Rajpathak S.N. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and metaanalysis. Diabetes Obes Metab. 2014;16(5):410–417. https://doi.org/10.1111/dom.12233.Zhang Y., McCoy R.G., Mason J.E., Smith S.A., Shah N.D., Denton B.T. et al. Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care. 2014;37(5):1338–1345. https://doi.org/10.2337/dc13-1901.Zhang Y., McCoy R.G., Mason J.E., Smith S.A., Shah N.D., Denton B.T. et al. Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care. 2014;37(5):1338–1345. https://doi.org/10.2337/dc13-1901.Blonde L., Wogen J., Kreilick C., Seymour A.A. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide-metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab. 2003;5(6):424–431. https://doi.org/10.1046/j.1463-1326.2003.00297.x.Blonde L., Wogen J., Kreilick C., Seymour A.A. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide-metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab. 2003;5(6):424–431. https://doi.org/10.1046/j.1463-1326.2003.00297.x.Duckworth W., Marcelli M., Padden M. et al. Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets. J Manag Care Pharm. 2003;9(3):256–262. https://doi.org/10.18553/jmcp.2003.9.3.256.Duckworth W., Marcelli M., Padden M. et al. Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets. J Manag Care Pharm. 2003;9(3):256–262. https://doi.org/10.18553/jmcp.2003.9.3.256.Lim P.C., Lim S.L., Oiyammaal C. Glycaemic control and cost analysis when changing from gliclazide co-administered with metformin to pre-combined glibenclamide-metformin tablets in type 2 diabetes mellitus. Med J Malaysia. 2012;67(1):21–24. Available at: https://pubmed.ncbi.nlm.nih.gov/22582544.Lim P.C., Lim S.L., Oiyammaal C. Glycaemic control and cost analysis when changing from gliclazide co-administered with metformin to pre-combined glibenclamide-metformin tablets in type 2 diabetes mellitus. Med J Malaysia. 2012;67(1):21–24. Available at: https://pubmed.ncbi.nlm.nih.gov/22582544.Cheong C., Barner J.C., Lawson K.A., Johnsrud M.T. Patient adherence and reimbursement amount for antidiabetic fixed dose combination products compared with dual therapy among texas medicaid recipients. Clin Ther. 2008;30(10):1893–1907. https://doi.org/10.1016/j.clinthera.2008.10.003.Cheong C., Barner J.C., Lawson K.A., Johnsrud M.T. Patient adherence and reimbursement amount for antidiabetic fixed dose combination products compared with dual therapy among texas medicaid recipients. Clin Ther. 2008;30(10):1893–1907. https://doi.org/10.1016/j.clinthera.2008.10.003.Charpentier G., Fleury F., Kabir M., Vaur L., Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabetic Medicine. 2001;18(10):828–834. https://doi.org/10.1046/j.1464-5491.2001.00582.x.Charpentier G., Fleury F., Kabir M., Vaur L., Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabetic Medicine. 2001;18(10):828–834. https://doi.org/10.1046/j.1464-5491.2001.00582.x.Müller G., Hartz D., Pünter J., Okonomopulos R., Kramer W. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. Biochimica et Biophysica Acta. 1994;1191(2):267–277. https://doi.org/10.1016/0005-2736(94)90177-5.Müller G., Hartz D., Pünter J., Okonomopulos R., Kramer W. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. Biochimica et Biophysica Acta. 1994;1191(2):267–277. https://doi.org/10.1016/0005-2736(94)90177-5.Shukla U.A., Chi E.M., Lehr K.H. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. Annals of Pharmacotherapy. 2004;38(1):30–35. https://doi.org/10.1345/aph.1C397.Shukla U.A., Chi E.M., Lehr K.H. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. Annals of Pharmacotherapy. 2004;38(1):30–35. https://doi.org/10.1345/aph.1C397.Matsuki M., Matsuda M., Kohara K., Shimoda M., Kanda Y., Tawaramoto K. et al. Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of onceversus twice-daily dosing. Endocrine Journal. 2007;54(4):571–576. https://doi.org/10.1507/endocrj.k06-052.Matsuki M., Matsuda M., Kohara K., Shimoda M., Kanda Y., Tawaramoto K. et al. Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of onceversus twice-daily dosing. Endocrine Journal. 2007;54(4):571–576. https://doi.org/10.1507/endocrj.k06-052.Rosenkranz B., Profozic V., Metelko Z., Mrzljak V., Lange C., Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996;39(12):1617–1624. https://doi.org/10.1007/s001250050624.Rosenkranz B., Profozic V., Metelko Z., Mrzljak V., Lange C., Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996;39(12):1617–1624. https://doi.org/10.1007/s001250050624.Pareek A., Chandurkar N.B., Salkar H.R., Borkar M.S., Tiwari D. Evaluation of efficacy and tolerability of glimepiride and metformin combination: a multicentric study in patients with type-2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin. Am J Ther. 2013;20(1):41–47. https://doi.org/10.1097/MJT.0b013e3181ff7c63.Pareek A., Chandurkar N.B., Salkar H.R., Borkar M.S., Tiwari D. Evaluation of efficacy and tolerability of glimepiride and metformin combination: a multicentric study in patients with type-2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin. Am J Ther. 2013;20(1):41–47. https://doi.org/10.1097/MJT.0b013e3181ff7c63.González-Ortiz M., Guerrero-Romero J.F., Violante-Ortiz R., Wacher-Rodarte N., Martínez-Abundis E., Aguilar-Salinas C. et al. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complications. 2009;23(6):376–379. https://doi.org/10.1016/j.jdiacomp.2008.09.002.González-Ortiz M., Guerrero-Romero J.F., Violante-Ortiz R., Wacher-Rodarte N., Martínez-Abundis E., Aguilar-Salinas C. et al. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complications. 2009;23(6):376–379. https://doi.org/10.1016/j.jdiacomp.2008.09.002.Мкртумян А.М. Результаты наблюдательного исследования ESCALATION: особенности применения глимепирида у пациентов с сахарным диабетом 2-го типа, не достигших целевых показателей углеводного обмена на фоне терапии ингибитором ДПП-4 в комбинации с метформином. Проблемы эндокринологии. 2017;63(1):30–38. https://doi.org/10.14341/probl201763131-38.Mkrtumyan A.M. The Clinical use of glimepiride in patients with type 2 diabetes mellitus, uncontrolled on combination of DPP4-inhibitors and metformin: results of ESCALATION observational study. Problemy Endokrinologii. 2017;63(1):30–38. (In Russ.) https://doi.org/10.14341/probl201763131-38.Perkovic V., Heerspink H.L., Chalmers J., Woodward M., Jun M., Li Q. et al; ADVANCE Collaborative Group. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 2013;83(3):517–523. https://doi.org/10.1038/ki.2012.401.Perkovic V., Heerspink H.L., Chalmers J., Woodward M., Jun M., Li Q. et al; ADVANCE Collaborative Group. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 2013;83(3):517–523. https://doi.org/10.1038/ki.2012.401.ADVANCE Collaborative Group, Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. https://doi.org/10.1056/NEJMoa0802987.ADVANCE Collaborative Group, Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. https://doi.org/10.1056/NEJMoa0802987.Oellgaard J., Gæde P., Rossing P., Persson F., Parving H.H., Pedersen O. Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. Kidney Int. 2017;91(9):982–988. https://doi.org/10.1016/j.kint.2016.11.023.Oellgaard J., Gæde P., Rossing P., Persson F., Parving H.H., Pedersen O. Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. Kidney Int. 2017;91(9):982–988. https://doi.org/10.1016/j.kint.2016.11.023.Katakami N., Yamasaki Y., Hayashi-Okano R., Ohtoshi K., Kaneto H., Matsuhisa M. et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004;47(11):1906–1913. https://doi.org/10.1007/s00125-004-1547-8.Katakami N., Yamasaki Y., Hayashi-Okano R., Ohtoshi K., Kaneto H., Matsuhisa M. et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004;47(11):1906–1913. https://doi.org/10.1007/s00125-004-1547-8.Шестакова М.В., Викулова О.К. Результаты открытой наблюдательной программы DIAMOND. Сахарный диабет. 2011;14(3):96–102. https://doi.org/10.14341/2072-0351-6232.Shestakova M.V., Vikulova O.K. The results of open observational trial DIAMOND. Diabetes Mellitus. 2011;14(3):96–102. (In Russ.) https://doi.org/10.14341/2072-0351-6232.Аметов А.С., Бутаева С.Г. Комбинированная сахароснижающая терапия: иДПП-4 в сравнении с сульфонилмочевиной. Эндокринологи: новости, мнения, обучение. 2018;7(1):76–81. https://doi.org/10.24411/2304-9529-2018-00008.Ametov A.S., Butaeva S.G. Combined hypoglycemic therapy: iDPP-4 in comparison with sulfonylureas. Endocrinology: News, Opinions, Training. 2018;7(1):76–81. (In Russ.) https://doi.org/10.24411/2304-9529-2018-00008.Zaccardi F., Jacquot E., Cortese V., Tyrer F., Seidu S., Davies M.J., Khunti K. Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes, Obes Metab. 2020;22(12):2417–2426. https://doi.org/10.1111/dom.14169.Zaccardi F., Jacquot E., Cortese V., Tyrer F., Seidu S., Davies M.J., Khunti K. Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes, Obes Metab. 2020;22(12):2417–2426. https://doi.org/10.1111/dom.14169.Maloney A., Rosenstock J., Fonseca V. A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. Clin Pharmacol Ther. 2019;105(5):1213–1223. https://doi.org/10.1002/cpt.1307.Maloney A., Rosenstock J., Fonseca V. A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. Clin Pharmacol Ther. 2019;105(5):1213–1223. https://doi.org/10.1002/cpt.1307.

The authors declare that there are no conflicts of interest present.